Nordicus Partners Corporation Acquires Bio-Convert ApS
Nordicus Partners (OTCQB: NORD) has announced an agreement to acquire Bio-Convert ApS, a Denmark-based clinical-stage biopharmaceutical company, in an all-stock transaction of 12 million restricted common shares. Bio-Convert specializes in developing treatments for oral leukoplakia, a potentially malignant disorder that can lead to oral cancer. The company is developing a proprietary mucoadhesive oral formulation that delivers medication without systemic absorption, aiming to eliminate lesions or reduce the malignant conversion rate to oral cancer. Bio-Convert plans to conduct a pilot efficacy study in patients with oral leukoplakia.
Nordicus Partners (OTCQB: NORD) ha annunciato un accordo per acquisire Bio-Convert ApS, un'azienda biofarmaceutica danese in fase clinica, in un'operazione interamente azionaria di 12 milioni di azioni ordinarie soggette a restrizioni. Bio-Convert si specializza nello sviluppo di trattamenti per la leucoplachia orale, un disturbo potenzialmente maligno che può portare al cancro orale. L'azienda sta sviluppando una formulazione orale mucoadesiva proprietaria che consente la somministrazione di farmaci senza assorbimento sistemico, con l'obiettivo di eliminare le lesioni o ridurre il tasso di conversione maligna in cancro orale. Bio-Convert prevede di condurre uno studio pilota di efficacia su pazienti con leucoplachia orale.
Nordicus Partners (OTCQB: NORD) ha anunciado un acuerdo para adquirir Bio-Convert ApS, una empresa biofarmacéutica danesa en etapa clínica, en una transacción completamente en acciones de 12 millones de acciones comunes restringidas. Bio-Convert se especializa en el desarrollo de tratamientos para la leucoplasia oral, un trastorno potencialmente maligno que puede conducir al cáncer oral. La empresa está desarrollando una formulación oral mucoadhesiva propietaria que proporciona medicación sin absorción sistémica, con el objetivo de eliminar lesiones o reducir la tasa de conversión maligna al cáncer oral. Bio-Convert planea llevar a cabo un estudio piloto de eficacia en pacientes con leucoplasia oral.
Nordicus Partners (OTCQB: NORD)는 덴마크에 본사를 둔 임상 단계 생물 제약 회사인 Bio-Convert ApS를 1200만 주의 제한된 보통주를 거래하는 전량 주식 거래로 인수하기로 합의했다고 발표했습니다. Bio-Convert는 구강 암으로 이어질 수 있는 잠재적으로 악성 질환인 구강 백반증 치료제를 개발하는 데 특화되어 있습니다. 이 회사는 약물이 전신 흡수 없이 전달되는 독자적인 점막 부착성 경구 제형을 개발하고 있으며, 이는 병변을 제거하거나 구강 암으로의 악성 변환 비율을 줄이는 것을 목표로 하고 있습니다. Bio-Convert는 구강 백반증 환자를 대상으로 파일럿 효능 연구를 실시할 계획입니다.
Nordicus Partners (OTCQB: NORD) a annoncé un accord pour acquérir Bio-Convert ApS, une entreprise biopharmaceutique danoise en phase clinique, dans le cadre d'une transaction entièrement en actions de 12 millions d'actions ordinaires restreintes. Bio-Convert se spécialise dans le développement de traitements pour la leucoplasie orale, un trouble potentiellement malin qui peut mener au cancer buccal. L'entreprise développe une formulation orale mucoadhésive propriétaire qui délivre des médicaments sans absorption systémique, visant à éliminer les lésions ou à réduire le taux de conversion malin en cancer buccal. Bio-Convert prévoit de réaliser une étude pilote de l'efficacité chez des patients souffrant de leucoplasie orale.
Nordicus Partners (OTCQB: NORD) hat eine Vereinbarung zur Übernahme von Bio-Convert ApS, einem in Dänemark ansässigen Biopharmaunternehmen in der klinischen Phase, in einer vollständig aktienbasierten Transaktion von 12 Millionen beschränkten Stammaktien bekannt gegeben. Bio-Convert ist auf die Entwicklung von Behandlungen für orale Leukoplakie spezialisiert, eine potenziell bösartige Erkrankung, die zu Mundkrebs führen kann. Das Unternehmen entwickelt eine proprietäre mucoadhäsive orale Formulierung, die Medikamente ohne systemische Aufnahme abgibt, mit dem Ziel, Läsionen zu beseitigen oder die bösartige Umwandlungsrate in Mundkrebs zu reduzieren. Bio-Convert plant, eine Pilotstudie zur Wirksamkeit bei Patienten mit oraler Leukoplakie durchzuführen.
- Acquisition expands company portfolio into clinical-stage biopharmaceuticals
- Enters oral cancer treatment market with proprietary drug delivery technology
- All-stock transaction preserves cash resources
- 12 million share issuance will cause significant shareholder dilution
- Acquisition target is still in clinical stage with no approved products
- No immediate revenue generation from the acquired company
Beverly Hills, California., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. life sciences companies with optimal conditions to establish themselves on the U.S. market, today announced that it entered into an agreement with Bio-Convert ApS (“Bio-Convert”) to acquire
Bio-Convert is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of oral leukoplakia, which is a potentially malignant disorder affecting the oral mucosa. Oral leukoplakia is a white patch or plaque that can develop in the oral cavity and cause oral cancer. Bio-Convert is developing a new pharmaceutical drug product for the treatment of oral leukoplakia and the prevention of oral cancer formation.
About Bio-Convert ApS
Bio-Convert ApS, a Denmark-based clinical-stage biopharmaceutical company, is aiming to revolutionize the treatment of oral leukoplakia, by minimizing or removing oral leukoplakia lesions, that further reduces the risk of patients developing oral cancer from it.
Bio-Convert has initiated new activities in the field of oral cancer, which involves developing a new drug formulation for the treatment of oral leukoplakia. This is achieved through a proprietary mucoadhesive oral formulation that delivers the drug without any systemic absorption. The aim of the treatment is therefore to eliminate the lesions or to reduce the malignant conversion rate of oral leukoplakia to oral cancer. The effect on oral cancer may improve the surgical removal procedure should this be needed for the oral cancer patients.
Bio-Convert’s current plan is to conduct a pilot efficacy study in patients with oral leukoplakia. For more information about Bio-Convert, please visit: www.bio-convert.com
About Nordicus Partners Corporation
Nordicus Partners Corporation specializes in providing Nordic and U.S. life sciences companies with the best possible conditions to establish themselves on the U.S. market, taking advantage of management’s combined +90 years of experience in the corporate sector, serving in different capacities both domestically and globally. Nordicus’ core competencies lie in assisting Danish as well as other Nordic and U.S. companies in different areas of corporate finance activities, such as: business- and market development, growth strategies, attracting the right people, partners and capital for businesses and company acquisitions and sales. In May 2024 Nordicus bought
Forward-Looking Statements
The Company believes that this press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Terms such as “may,” “might,” “would,” “should,” “could,” “project,” “estimate,” “pro-forma,” “predict,” “potential,” “strategy,” “anticipate,” “attempt,” “develop,” “plan,” “help,” “believe,” “continue,” “intend,” “expect,” “future,” and terms of similar import (including the negative of any of these terms) may identify forward-looking statements. Such forward-looking statements, including but not limited to statements regarding the plans and objectives of management for future operations, are based on management’s current expectations and are subject to risks and uncertainties that could cause results to differ materially from the forward-looking statements. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the accuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, market acceptance of the company’s products and services; competition from existing products or new products that may emerge; the implementation of the company’s business model and strategic plans for its business and our products; estimates of the company’s future revenue, expenses, capital requirements and need for financing; current and future government regulations; and developments relating to the company’s competitors. Readers are cautioned not to place undue reliance on forward-looking statements because of the risks and uncertainties related to them. For further information on such risks and uncertainties, you are encouraged to review the Company’s filings with the Securities and Exchange Commission (“SEC”), including its Annual Report on Form 10-K for the fiscal year ended March 31, 2024 and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024. The Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments, except as required by law.
For further information contact
Mr. Henrik Rouf
Chief Executive Officer
Phone +1 310 666.0750
Email hr@nordicuspartners.com
FAQ
What is the acquisition price for Bio-Convert ApS by Nordicus Partners (NORD)?
What is Bio-Convert ApS developing and what is their main focus?
What stage of development is Bio-Convert's treatment currently in?
How will the Bio-Convert acquisition affect Nordicus Partners (NORD) shareholders?
